oncotarget: sacituzumab govitecan in triple-negative breast cancer
Published 3 years ago • 148 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
5:16
study of sacituzumab govitecan for triple-negative breast cancer
-
1:13
crosstalk between triple negative breast cancer and microenvironment | oncotarget
-
2:17
sacituzumab govitecan with platinum chemotherapy: antitumor effects | oncotarget
-
2:40
dr. bardia on sacituzumab govitecan in triple-negative breast cancer
-
1:36
real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
0:59
oncotarget: crispr used in triple negative breast cancer research
-
0:41
oncotarget: combination therapeutics inhibit breast cancer resistance
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
-
1:49
final os analysis of sacituzumab govitecan in tropics-02
-
2:01
ascent: sacituzumab govitecan outperforms chemo in black patients with tnbc
-
6:17
antibody-drug conjugates in tnbc: sacituzumab govitecan
-
4:25
ascent: sacituzumab govitecan shows promise in mtnbc patients
-
3:10
ascent trial: sacituzumab govitecan for tnbc
-
4:17
treatment options in metastatic tnbc
-
1:00
dr. burris on the utility of sacituzumab govitecan in metastatic tnbc
-
2:16
efficacy of sacituzumab govitecan by trop-2 expression in patients with muc
-
1:47
dr. bardia on sacituzumab govitecan in tnbc
-
2:15
ascent: sacituzumab govitecan biomarker analysis